Mimi Leung

Janssen (Belgium) — Belgium

Medicine · Health Sciences

11h-index6.1kcitations23works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(15), RNA Interference and Gene Delivery(5), Cancer Immunotherapy and Biomarkers(4), Virus-based gene therapy research(4), Viral Infectious Diseases and Gene Expression in Insects(4)

Publications23 total

258 First-in-human results from a phase 1 single- and multiple-ascending dose study in healthy participants assessing the safety, pharmacokinetics, and pharmacodynamics of the interleukin-17A inhibitor JNJ-81241459
Journal of Investigative Dermatology·2023Open Access
Supplementary Data from Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
2023Open Access
Data from Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
2023Open Access
Data from Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Data from Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
2023Open Access
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
Journal for ImmunoTherapy of Cancer·2021· 61 citedOpen Access
Abstract CT287: CANOPY-A: A phase III, multicenter, randomized trial evaluating canakinumab versus placebo as adjuvant therapy in patients with completely resected non-small cell lung cancer (NSCLC)
Cancer Research·2020
CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology·2020· 6 cited
CANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC
Annals of Oncology·2019Open Access
PD01.04 CANOPY-A: a Phase 3 Study of Canakinumab as Adjuvant Therapy in Patients with Surgically Resected NSCLC
Journal of Thoracic Oncology·2019
Tisagenlecleucel Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells
CPT Pharmacometrics & Systems Pharmacology·2019· 140 citedOpen Access
Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: Updated Analysis of the ELIANA Clinical Trial
Biology of Blood and Marrow Transplantation·2019· 17 citedOpen Access
Industry’s Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy
Current Hematologic Malignancy Reports·2019· 17 citedOpen Access
Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia
Blood·2018· 91 cited
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
Clinical Cancer Research·2018· 218 citedOpen Access
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
New England Journal of Medicine·2018· 5.4k citedOpen Access
Pharmacokinetics and Pharmacodynamics of Tocilizumab for the Management of Cytokine Release Syndrome (CRS) in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with CAR T-Cell Therapy, CTL019
Blood·2017· 1 cited
CTL019 Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor (CAR) T Cells to Characterize the Impact of Tocilizumab on Expansion and to Identify Correlates of Cytokine Release Syndrome Severity
Blood·2017· 7 cited
CTL019 Clinical Pharmacology and Biopharmaceutics in Pediatric Patients with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
Clinical Lymphoma Myeloma & Leukemia·2017· 6 cited
Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study
Journal of Cancer Research and Clinical Oncology·2015· 53 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Stephan A. Grupp(14), Shannon L. Maude(13), Michael A. Pulsipher(13), Theodore W. Laetsch(12), Carl H. June(11), Patricia A. Wood(11), Karen Thudium Mueller(11), Michael W. Boyer(10), John E. Levine(9), Keith J. August(9), Rakesh Awasthi(9), Tetiana Taran(8), Bruce L. Levine(8), Lori Tomassian(8), Andrew M. Stein(7), Sweta Shah(7), Edward Waldron(6), Jason S. Hamilton(6), Denise Sickert(6), Abhijit Chakraborty(6)